Loralee B. Rupp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Loralee B. Rupp has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Mei Lu
School of Medicine Michigan State University East Lansing Michigan USA
10 shared publications - Mark A. Schmidt
Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, USA
9 shared publications - Stuart C. Gordon
Division of Gastroenterology and Hepatology Henry Ford Health Detroit Michigan USA
9 shared publications - Meng-Hua Tao
Department of Public Health Sciences, Henry Ford Health, Detroit, USA
8 shared publications - Sheri Trudeau
Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
8 shared publications - Trueman Wu
Department of Public Health Sciences Henry Ford Health Detroit Michigan USA
8 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background:Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers.Methods:A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk.Results:After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers.Conclusions:Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs.Impact:Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 4 shows characteristics of HCV patients at baseline for breast cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 6 describes distribution of identified primary NHL cases based on morphology type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 2 describes characteristics of HCV patients at baseline for lung cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 1 shows ICD-O-3 codes used to identify interested primary extrahepatic cancers
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 5 shows characteristics of HCV patients at baseline for prostate cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Supplementary Table 3 describes characteristics of HCV patients at baseline for NHL
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 28 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2025-2031
Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Background: Antiviral treatment for hepatitis C virus (HCV) has been shown to reduce risk of liver cancer, but there are few studies on its impact on the risk of non-liver cancers. We used a large cohort of patients with HCV with extensive follow-up to investigate whether receipt of antiviral therapy affects the risk of extrahepatic cancers. Methods: A total of 17,485 patients with HCV were followed until incidence of lung cancer, non–Hodgkin lymphoma (NHL), breast or prostate cancer, death, or last follow-up. We used multivariable modeling with time-varying covariates and propensity scores to adjust for treatment selection bias; we also applied generalized estimating equations with a multinominal link function for discrete time-to-event data. Death was considered a competing risk. Results: After 15 years of follow-up, we identified 408 incident cases of cancers, namely 140 lung, 72 NHL, 81 breast (female), and 115 prostate cancer cases. Compared with no treatment, patients who receive either direct-acting antivirals or IFN-based treatment had significantly lower risk of lung cancer [HR = 0.35, 95% confidence interval, 0.24−0.52 for achieving sustained virologic response (SVR); HR = 0.34, 95% confidence interval, 0.21−0.55 for treatment failure]. Risk of NHL was reduced only among patients who achieved SVR. There were no significant associations between antiviral therapy and risks of breast and prostate cancers. Conclusions: Antiviral treatment for HCV independently reduced the risk of lung cancer, whereas the protective association with NHL was limited to patients achieving SVRs. Impact: Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
- 1 August 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (8) , 1333-1341.e6
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems
- 1 August 2018
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (8) , 1333-1341.e6
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems
- 10 August 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (12) , 3469-3477
Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study
Background Linking persons with hepatitis C virus (HCV) to care and treatment is critical to reduction in disease burden; typically, this entailed referral to a specialist. However, data regarding the frequency and factors associated with referral among patients in healthcare organizations (HCOs) are lacking. Methods Among persons in four US HCOs with newly diagnosed HCV during 2006–2011, we determined the frequency of liver-related specialist care after diagnosis. We also identified sociodemographic and clinical characteristics associated with such care by multivariate analysis, adjusted for all variables. Results Among 3592 patients with newly diagnosed HCV, 57 % (range among sites 45–90 %) received specialist care; of these, 57 % received care within 90 days of diagnosis. Patient characteristics associated with receipt of specialist care included: affiliation with one of the study sites [adjusted odds ratio (aOR) 4.8 vs. the referent site); having Medicare plus private insurance (aOR 1.6 vs. Medicaid); and having elevated alanine aminotransferase (ALT) (aOR 1.6 vs. normal ALT) or lower platelet values (aOR 1.4 vs. normal platelet level). Specialist care within 90 days of diagnosis was associated with private insurance (aOR 1.5 vs. Medicaid), elevated ALT levels (aOR 1.3–2.3 vs. normal), and having ≥2 comorbid conditions (aOR 1.4 vs. no comorbid conditions). Compared to patients not referred, those referred were more likely to be treated (aOR 3.5). Conclusions Receipt of specialist care among persons with newly diagnosed HCV varied among HCOs. Clinical evidence of liver disease and having private insurance were associated with prompt receipt of specialist care and HCV treatment.
- 10 August 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (12) , 3469-3477
Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study
Background Linking persons with hepatitis C virus (HCV) to care and treatment is critical to reduction in disease burden; typically, this entailed referral to a specialist. However, data regarding the frequency and factors associated with referral among patients in healthcare organizations (HCOs) are lacking. Methods Among persons in four US HCOs with newly diagnosed HCV during 2006–2011, we determined the frequency of liver-related specialist care after diagnosis. We also identified sociodemographic and clinical characteristics associated with such care by multivariate analysis, adjusted for all variables. Results Among 3592 patients with newly diagnosed HCV, 57 % (range among sites 45–90 %) received specialist care; of these, 57 % received care within 90 days of diagnosis. Patient characteristics associated with receipt of specialist care included: affiliation with one of the study sites [adjusted odds ratio (aOR) 4.8 vs. the referent site); having Medicare plus private insurance (aOR 1.6 vs. Medicaid); and having elevated alanine aminotransferase (ALT) (aOR 1.6 vs. normal ALT) or lower platelet values (aOR 1.4 vs. normal platelet level). Specialist care within 90 days of diagnosis was associated with private insurance (aOR 1.5 vs. Medicaid), elevated ALT levels (aOR 1.3–2.3 vs. normal), and having ≥2 comorbid conditions (aOR 1.4 vs. no comorbid conditions). Compared to patients not referred, those referred were more likely to be treated (aOR 3.5). Conclusions Receipt of specialist care among persons with newly diagnosed HCV varied among HCOs. Clinical evidence of liver disease and having private insurance were associated with prompt receipt of specialist care and HCV treatment.